Abstract:BACKGROUND:Treat-to-target goals for patients with systemic lupus erythematosus (SLE) have been validated to protect against organ damage and to improve quality of life. We aimed to investigate the association between lupus low disease activity state (LLDAS) and remission and risk of mortality in patients with SLE. We hypothesised that LLDAS has a protective association with mortality risk.METHODS:In this prospective, multinational, longitudinal cohort study, we used data from patients with SLE in the Asia Pacific Lupus Collaboration cohort collected between May 1, 2013, and Dec 31, 2020. Eligible patients were adults (aged ≥18 years) who met either the 1997 American College of Rheumatology modified classification criteria for SLE or the 2012 Systemic Lupus International Collaborating Clinics classification criteria. The primary outcome was all-cause mortality, and LLDAS, remission, and variations of remission with lower glucocorticoid thresholds were the primary exposure variables. Survival analyses were used to examine longitudinal associations between these endpoints and risk of mortality. This study is registered with ClinicalTrials.gov, NCT03138941.FINDINGS:Among a total of 4106 patients in the cohort, 3811 (92·8%) patients were included in the final analysis (median follow-up 2·8 years [IQR 1·0-5·3]; 3509 [92·1%] women and 302 [7·9%] men), of whom 80 died during the observation period (crude mortality rate 6·4 deaths per 1000 person-years). LLDAS was attained at least once in 43 (53·8%) of 80 participants who died and in 3035 (81·3%) of 3731 participants who were alive at the end of the study (p<0·0001); 22 (27·5%) participants who died versus 1966 (52·7%) who were alive at the end of the study attained LLDAS for at least 50% of observed time (p<0·0001). Remission was attained by 32 (40·0%) of 80 who died and in 2403 (64·4%) of 3731 participants who were alive at the end of the study (p<0·0001); 14 (17·5%) participants who died versus 1389 (37·2%) who were alive at the end of the study attained remission for at least 50% of observed time (p<0·0001). LLDAS for at least 50% of observed time (adjusted hazard ratio 0·51 [95% CI 0·31-0·85]; p=0·010) and remission for at least 50% of observed time (0·52 [0·29-0·93]; p=0·027) were associated with reduced risk of mortality. Modifying the remission glucocorticoid threshold (<5·0 mg/day prednisolone) was more protective against mortality than current remission definitions (0·31 [0·12-0·77]; p=0·012), and glucocorticoid-free remission was the most protective (0·13 [0·02-0·96]; p=0·046).INTERPRETATION:LLDAS significantly reduced the risk of mortality in patients with SLE. Remission did not further reduce the risk of mortality compared with LLDAS, unless lower glucocorticoid thresholds were used.FUNDING:The Asia-Pacific Lupus Collaboration received funding from Janssen, Bristol Myers Squibb, Eli Lilly, and UCB for this study.

Association of antimalarial drugs with decreased overall and cause specific mortality in systemic lupus erythematosus

Causes of Death in Hospitalized Patients with Systemic Lupus Erythematosus: a 10-Year Multicenter Nationwide Chinese Cohort

Protective effects of antimalarials in Chinese patients with systemic lupus erythematosus

Comparison of Short Interval and Low Dose (SILD) with High Dose of Cyclophosphamide in the Susceptibility to Infection in SLE: a Multicentrereal-World Study

462 Antimalarials Improve Survival of Systemic Lupus Erythematosus on Cholesterol: Results of a Fifteen-Year Chinese Multicenter Retrospective Study in Jiangsu Province

Prognosis for Hospitalized Patients with Systemic Lupus Erythematosus in China: 5-Year Update of the Jiangsu Cohort

Low Dosage Use of Cyclophosphamide Improves the Survival of Patients with Systemic Lupus Erythematosus.

Creatinine clearance rate predicts prognosis of patients with systemic lupus erythematosus: a large retrospective cohort study

Comparison of Contributors to Mortality Differences in SLE Patients with Different Initial Disease Activity: A Larger Multicenter Cohort Study

Prognostic Indicators Of Hospitalized Patients With Systemic Lupus Erythematosus: A Large Retrospective Multicenter Study In China

Antimalarials may reduce cancer risk in patients with systemic lupus erythematosus: a systematic review and meta-analysis of prospective studies

412 Mortality in Chinese Patients with Systemic Lupus Erythematosus

Mortality and prognostic factors among inpatients with systemic lupus erythematosus in China: A 20-year retrospective study

Association of Higher Hydroxychloroquine Blood Levels With Reduced Thrombosis Risk in Systemic Lupus Erythematosus

The Presumable Effects of Hydroxychloroquine and Its Metabolites in the Treatment of Systemic Lupus Erythematosus.

Long-term mortality and morbidity of patients with systemic lupus erythematosus: a single-center cohort study in China.

Death-related factors of systemic lupus erythematosus patients associated with the course of disease in Chinese populations: multicenter and retrospective study of 1,958 inpatients

Mortality in patients with systemic lupus erythematosus: A meta-analysis of overall and cause-specific effects

Antipsychotics Reduces Mortality in Patients with Neuropsychiatric Systemic Lupus Erythematosus: a Retrospective Study of Psychiatric Consultation Cases

Mortality and prognostic factors in Chinese patients with systemic lupus erythematosus.

Lupus Low Disease Activity State and Remission and Risk of Mortality in Patients with Systemic Lupus Erythematosus: a Prospective, Multinational, Longitudinal Cohort Study